[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100325721":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":35,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":7,"maxAge":7,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Zhongtao Zhang, M.D.","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+86-13801060364","zhangzht@ccmu.edu.cn",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Mengyi Li, M.D.","+86-15810993198","muzi_1990@126.com",[22],{"facility":5,"status":23,"city":24,"state":7,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Beijing","China","CN",{"type":28,"coordinates":29},"Point",[30,31],116.39723,39.9075,{"lat":31,"lon":30},[34],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"type":11,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Zhongtao Zhang","Director of general surgery, principal investigator","100325721","beijing-friendship-hospital-metabolic-surgery-database-100325721",false,"NCT03520699","Beijing Friendship Hospital Metabolic Surgery Database","Beijing Friendship Hospital Metabolic Surgery Clinical Database","Inclusion Criteria:\n\n* be able to receive metabolic surgery (LSG or LRYGB)\n\nExclusion Criteria:\n\n* can not be able to understand and willing to participate in this registry with signature","ALL",{"count":47,"type":48},3000,"ESTIMATED","3 Months","OBSERVATIONAL","Metabolic surgery, as a recognition treatment option for patients with clinical morbid obesity, is gaining increasing appreciation. In addition to substantial weight loss, emerging studies have highlighted that metabolic surgery can substantially ameliorate obesity-related metabolic diseases, including but not limited to type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, obstructive sleep apnea-hypopnea syndrome (OSAHS) and polycystic ovary syndrome (PCOS)in severely obese patients. However, further investigations with larger sample size and longer observation time still needed to clarity the efficacy and safety of metabolic surgery in Chinese patients with obesity and encouraging future research in this field.",[53],"Metabolic Surgery",[55,56],"metabolic surgery","metabolic disease","2019-09-09",{"date":59,"type":60},"2019-09-10","ACTUAL",{"date":62,"type":60},"2017-12-01",{"date":64,"type":48},"2028-12-31",{"name":5,"class":6},1]